Humacyte, Inc. Common Stock (HUMA)
Humacyte, Inc. is a biotechnology company focused on developing regenerative medicine therapies using bioengineered human tissue. Its flagship product, HUMACYTE®, is a bioengineered human acellular tissue, primarily used for vascular and tissue replacement treatments. The company aims to innovate in the field of tissue engineering to address unmet medical needs in surgery, trauma, and vascular diseases.
Company News
The Russell 2000 index reached an all-time high after the Federal Reserve signaled potential interest rate cuts, boosting small-cap stocks and providing cheaper borrowing opportunities for smaller companies.
Humacyte reported Q2 2025 earnings with $0.30 million in GAAP revenue, falling short of $1.0 million analyst estimates. The company saw expanded hospital access for its lead product Symvess, with 82 civilian hospitals approved by quarter-end, and showed improved financial metrics through cost controls.
The Law Offices of Frank R. Cruz has filed class action lawsuits on behalf of shareholders of Wolfspeed, Humacyte, Xerox, and Zeta Global Holdings. The lawsuits allege that the companies made materially false and/or misleading statements about their business, operations, and prospects.
Humacyte, Inc. (HUMA) reachead $5.17 at the closing of the latest trading day, reflecting a -1.34% change compared to its last close.